Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
Atezolizumab plus bevacizumab combination therapy was approved worldwide for use in 2020. A 30% objective response rate with 8% complete response (CR) was achieved in a phase 3 IMbrave150 trial. Here, the change in the treatment strategy for hepatocellular carcinoma (HCC) using atezolizumab plus bev...
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-10, Vol.13 (21), p.5475 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 21 |
| container_start_page | 5475 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Kudo, Masatoshi |
| description | Atezolizumab plus bevacizumab combination therapy was approved worldwide for use in 2020. A 30% objective response rate with 8% complete response (CR) was achieved in a phase 3 IMbrave150 trial. Here, the change in the treatment strategy for hepatocellular carcinoma (HCC) using atezolizumab plus bevacizumab combination therapy is reviewed. The phase 3 IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab. The analysis of CR cases was effective in patients with poor conditions, particularly tumor invasion in the main portal trunk (Vp4), making the combination therapy a breakthrough for HCC treatment. The response rate of the combination therapy was 44% against intermediate-stage HCC. Such a strong tumor-reduction effect paves the way for curative conversion (ABC conversion) therapy and, therefore, treatment strategies for intermediate-stage HCC may undergo a significant shift in the future. As these treatment strategies are effective in maintaining liver function, even in elderly patients, the transition frequency to second-line treatments could also be improved. These strategies may be effective against nonalcoholic steatohepatitis-related hepatocellular carcinoma and WNT/β-catenin mutations to a certain degree. |
| doi_str_mv | 10.3390/cancers13215475 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8582435</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2596010874</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-8874c64288cd5748728ef1996291c0ff65f3336d6ea61c8ddb8f277d8bbcdee83</originalsourceid><addsrcrecordid>eNpdkc1r3DAQxUVpSUKSc25F0Esv2-jDluRLITVtUwikh81ZjOXxroItuZIdSP762mQb0ugyYuY3Dz09Qi44-yJlxS4dBIcpcyl4WejyHTkRTIuNUlXx_tX9mJznfM-WIyXXSh-RY1lozZXUJ2Sq9xB2PuzotEe6TQjTgGGivyFB63cD7WKi1zjCFB32_dxDojUk50McgN7ldfNqwqfY-6d5gIaO_ZzpN3wAd2jUcWh8gMnHQLd7TDA-npEPHfQZzw_1lNz9-L6trzc3tz9_1Vc3G1cYPW2M0YVThTDGtaVeWsJgx6tKiYo71nWq7KSUqlUIijvTto3phNataRrXIhp5Sr4-645zM2DrFmMJejsmP0B6tBG8_X8S_N7u4oM1pRGFLBeBzweBFP_MmCc7-Lz-AwSMc7airHRRlZyt6Kc36H2cU1jsrZRinC1uFurymXIp5pywe3kMZ3YN1b4Jddn4-NrDC_8vQvkXZYmhSg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2596010874</pqid></control><display><type>article</type><title>Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Kudo, Masatoshi</creator><creatorcontrib>Kudo, Masatoshi</creatorcontrib><description>Atezolizumab plus bevacizumab combination therapy was approved worldwide for use in 2020. A 30% objective response rate with 8% complete response (CR) was achieved in a phase 3 IMbrave150 trial. Here, the change in the treatment strategy for hepatocellular carcinoma (HCC) using atezolizumab plus bevacizumab combination therapy is reviewed. The phase 3 IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab. The analysis of CR cases was effective in patients with poor conditions, particularly tumor invasion in the main portal trunk (Vp4), making the combination therapy a breakthrough for HCC treatment. The response rate of the combination therapy was 44% against intermediate-stage HCC. Such a strong tumor-reduction effect paves the way for curative conversion (ABC conversion) therapy and, therefore, treatment strategies for intermediate-stage HCC may undergo a significant shift in the future. As these treatment strategies are effective in maintaining liver function, even in elderly patients, the transition frequency to second-line treatments could also be improved. These strategies may be effective against nonalcoholic steatohepatitis-related hepatocellular carcinoma and WNT/β-catenin mutations to a certain degree.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13215475</identifier><identifier>PMID: 34771637</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Angiogenesis ; Antitumor activity ; Bevacizumab ; Biliary tract ; Bilirubin ; Hepatocellular carcinoma ; Liver ; Liver cancer ; Medical prognosis ; Microenvironments ; Mutation ; Patients ; Portal vein ; Quality of life ; Response rates ; Review ; Survival ; Tumors ; Vascular endothelial growth factor ; Wnt protein ; β-Catenin</subject><ispartof>Cancers, 2021-10, Vol.13 (21), p.5475</ispartof><rights>2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the author. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-8874c64288cd5748728ef1996291c0ff65f3336d6ea61c8ddb8f277d8bbcdee83</citedby><cites>FETCH-LOGICAL-c487t-8874c64288cd5748728ef1996291c0ff65f3336d6ea61c8ddb8f277d8bbcdee83</cites><orcidid>0000-0002-4102-3474</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582435/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582435/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34771637$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kudo, Masatoshi</creatorcontrib><title>Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Atezolizumab plus bevacizumab combination therapy was approved worldwide for use in 2020. A 30% objective response rate with 8% complete response (CR) was achieved in a phase 3 IMbrave150 trial. Here, the change in the treatment strategy for hepatocellular carcinoma (HCC) using atezolizumab plus bevacizumab combination therapy is reviewed. The phase 3 IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab. The analysis of CR cases was effective in patients with poor conditions, particularly tumor invasion in the main portal trunk (Vp4), making the combination therapy a breakthrough for HCC treatment. The response rate of the combination therapy was 44% against intermediate-stage HCC. Such a strong tumor-reduction effect paves the way for curative conversion (ABC conversion) therapy and, therefore, treatment strategies for intermediate-stage HCC may undergo a significant shift in the future. As these treatment strategies are effective in maintaining liver function, even in elderly patients, the transition frequency to second-line treatments could also be improved. These strategies may be effective against nonalcoholic steatohepatitis-related hepatocellular carcinoma and WNT/β-catenin mutations to a certain degree.</description><subject>Angiogenesis</subject><subject>Antitumor activity</subject><subject>Bevacizumab</subject><subject>Biliary tract</subject><subject>Bilirubin</subject><subject>Hepatocellular carcinoma</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Medical prognosis</subject><subject>Microenvironments</subject><subject>Mutation</subject><subject>Patients</subject><subject>Portal vein</subject><subject>Quality of life</subject><subject>Response rates</subject><subject>Review</subject><subject>Survival</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><subject>Wnt protein</subject><subject>β-Catenin</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1r3DAQxUVpSUKSc25F0Esv2-jDluRLITVtUwikh81ZjOXxroItuZIdSP762mQb0ugyYuY3Dz09Qi44-yJlxS4dBIcpcyl4WejyHTkRTIuNUlXx_tX9mJznfM-WIyXXSh-RY1lozZXUJ2Sq9xB2PuzotEe6TQjTgGGivyFB63cD7WKi1zjCFB32_dxDojUk50McgN7ldfNqwqfY-6d5gIaO_ZzpN3wAd2jUcWh8gMnHQLd7TDA-npEPHfQZzw_1lNz9-L6trzc3tz9_1Vc3G1cYPW2M0YVThTDGtaVeWsJgx6tKiYo71nWq7KSUqlUIijvTto3phNataRrXIhp5Sr4-645zM2DrFmMJejsmP0B6tBG8_X8S_N7u4oM1pRGFLBeBzweBFP_MmCc7-Lz-AwSMc7airHRRlZyt6Kc36H2cU1jsrZRinC1uFurymXIp5pywe3kMZ3YN1b4Jddn4-NrDC_8vQvkXZYmhSg</recordid><startdate>20211030</startdate><enddate>20211030</enddate><creator>Kudo, Masatoshi</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4102-3474</orcidid></search><sort><creationdate>20211030</creationdate><title>Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy</title><author>Kudo, Masatoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-8874c64288cd5748728ef1996291c0ff65f3336d6ea61c8ddb8f277d8bbcdee83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Angiogenesis</topic><topic>Antitumor activity</topic><topic>Bevacizumab</topic><topic>Biliary tract</topic><topic>Bilirubin</topic><topic>Hepatocellular carcinoma</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Medical prognosis</topic><topic>Microenvironments</topic><topic>Mutation</topic><topic>Patients</topic><topic>Portal vein</topic><topic>Quality of life</topic><topic>Response rates</topic><topic>Review</topic><topic>Survival</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><topic>Wnt protein</topic><topic>β-Catenin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kudo, Masatoshi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kudo, Masatoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2021-10-30</date><risdate>2021</risdate><volume>13</volume><issue>21</issue><spage>5475</spage><pages>5475-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Atezolizumab plus bevacizumab combination therapy was approved worldwide for use in 2020. A 30% objective response rate with 8% complete response (CR) was achieved in a phase 3 IMbrave150 trial. Here, the change in the treatment strategy for hepatocellular carcinoma (HCC) using atezolizumab plus bevacizumab combination therapy is reviewed. The phase 3 IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab. The analysis of CR cases was effective in patients with poor conditions, particularly tumor invasion in the main portal trunk (Vp4), making the combination therapy a breakthrough for HCC treatment. The response rate of the combination therapy was 44% against intermediate-stage HCC. Such a strong tumor-reduction effect paves the way for curative conversion (ABC conversion) therapy and, therefore, treatment strategies for intermediate-stage HCC may undergo a significant shift in the future. As these treatment strategies are effective in maintaining liver function, even in elderly patients, the transition frequency to second-line treatments could also be improved. These strategies may be effective against nonalcoholic steatohepatitis-related hepatocellular carcinoma and WNT/β-catenin mutations to a certain degree.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>34771637</pmid><doi>10.3390/cancers13215475</doi><orcidid>https://orcid.org/0000-0002-4102-3474</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-10, Vol.13 (21), p.5475 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8582435 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Angiogenesis Antitumor activity Bevacizumab Biliary tract Bilirubin Hepatocellular carcinoma Liver Liver cancer Medical prognosis Microenvironments Mutation Patients Portal vein Quality of life Response rates Review Survival Tumors Vascular endothelial growth factor Wnt protein β-Catenin |
| title | Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T08%3A59%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changing%20the%20Treatment%20Paradigm%20for%20Hepatocellular%20Carcinoma%20Using%20Atezolizumab%20plus%20Bevacizumab%20Combination%20Therapy&rft.jtitle=Cancers&rft.au=Kudo,%20Masatoshi&rft.date=2021-10-30&rft.volume=13&rft.issue=21&rft.spage=5475&rft.pages=5475-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13215475&rft_dat=%3Cproquest_pubme%3E2596010874%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2596010874&rft_id=info:pmid/34771637&rfr_iscdi=true |